Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia. It offers other pipeline products which include Actalycabtagene autoleucel for B-lymphoid malignancies, HCAR2 for multiple myeloma, and HCAr3 for Glioblastoma multiforme, and neuroblastoma.
← All startups
ImmunoACT
Series BDeveloper of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia. It offers other pipeline products which include Actalycabtagene autoleucel for B-lymphoid malignancies, HCAR2 for multiple myeloma, and HCAr3 for Glioblastoma multiforme, and neuroblastoma.
About
Institutional investors
SINELaurus LabsBIRAC
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.